The current lipid management pathway includes 5 commonly prescribed medications, including statins and ezetimibe in primary care, and PCSK9 inhibitors in secondary care.
Recently, Inclisiran and Bempadoic Acid have been approved by NICE, to lower lipids, giving clinicians additional options. The AHSNs’ role is to support clinicians to understand where these drugs can be best deployed. Specifically, with Inclisiran, we are supporting primary care teams to have confidence in initiating timely adoption and prescribing within their primary care setting.
We are gathering tools and resources to support health and care professionals to optimise cholesterol management.
We are supporting primary care to implement innovative approaches to supplement current clinical assessment processes, underpinned by changes in pathways, workforce and data collection.
This programme is part of a joint AHSN-Accelerated Access Collaborative (AAC) programme of work delivered in partnership with the AAC Rapid Uptake Product (RUP) Lipid programme. The RUP for the lipid management element of the programme is a novel, NICE-approved clinical pathway, focusing on primary and secondary prevention.